{"nctId":"NCT02754882","briefTitle":"A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer","startDateStruct":{"date":"2016-07-05","type":"ACTUAL"},"conditions":["Lung Cancer","Non-small Cell Lung Cancer"],"count":763,"armGroups":[{"label":"Bevacizumab (Avastin)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Bevacizumab","Drug: Carboplatin","Drug: Paclitaxel"]},{"label":"SB8 (A proposed bevacizumab biosimilar)","type":"EXPERIMENTAL","interventionNames":["Drug: SB8","Drug: Carboplatin","Drug: Paclitaxel"]}],"interventions":[{"name":"Bevacizumab","otherNames":["Avastin®"]},{"name":"SB8","otherNames":["SB8 (A proposed bevacizumab biosimilar)"]},{"name":"Carboplatin","otherNames":[]},{"name":"Paclitaxel","otherNames":["Taxol"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Aged ≥ 18 years\n2. ECOG performance status of 0-1\n3. Histologically-confirmed metastatic or recurrent non-squamous non-small cell lung cancer\n4. At least one measurable lesion according to RECIST v1.1.\n5. Able to receive bevacizumab, carboplatin and paclitaxel based on adequate laboratory and clinical parameters\n\nExclusion Criteria:\n\n1. Diagnosis of small cell carcinoma of the lung or squamous cell carcinoma\n2. Sensitizing EGFR mutations or ALK rearrangements\n3. Increased risk of bleeding determined by investigator based on radiographic / clinical findings\n4. History of systemic chemotherapy administered in the first-line setting for metastatic or recurrent disease of NSCLC.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Best Overall Response (Best Overall Response Rate[ORR]) by 24 Weeks","description":"The best ORR was defined as the proportion of subjects whose best overall response was either Complete Response (CR) or Partial Response (PR) according to RECIST v1.1 during the induction treatment period by 24 weeks.\n\nCR: Disappearance of all target lesions. PR: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.8","spread":null},{"groupId":"OG001","value":"47.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival","description":"PFS is defined as the time from the date of Randomisation to the date of disease progression (progressive disease \\[PD\\]) or death regardless of the cause of death.\n\nPer Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.50","spread":null},{"groupId":"OG001","value":"7.90","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.50","spread":null},{"groupId":"OG001","value":"7.90","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"OS was defined as the time from the date of randomisation to the date of death regardless of the cause of death.\n\nSubjects who were alive at the time of analysis were censored at the date of last known alive.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.90","spread":null},{"groupId":"OG001","value":"15.80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.80","spread":null},{"groupId":"OG001","value":"15.80","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Response (DoR)","description":"DoR in subjects with response from documented tumour response until disease progression up to 12 months from randomisation of the last subject","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.38","spread":"3.773"},{"groupId":"OG001","value":"6.79","spread":"4.117"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.33","spread":"3.784"},{"groupId":"OG001","value":"6.81","spread":"4.177"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-related Adverse Events Using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v4.03","description":"After the end of treatment (EOT) visit, SAEs should be reported to the Sponsor if the Investigator becomes aware of them.\n\nSeverity Grade of NCI-CTCAE v4.03 Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL) (Instrumental ADL refers to preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc.) Grade 3: Severe or medically significant but not immediately life-threatening; hospitalisation or prolongation of hospitalisation indicated; disabling; limiting self-care ADL (Self-care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden.) Grade 4: Life-threatening consequences; urgent intervention indicated Grade 5: Death related to AE","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"348","spread":null},{"groupId":"OG001","value":"346","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"57","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"127","spread":null},{"groupId":"OG001","value":"134","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"119","spread":null},{"groupId":"OG001","value":"97","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"31","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"27","spread":null}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics: Trough Level [Ctrough]","description":"Ctrough at selected cycles (i.e., Cycle 1, 3, 5 and 7)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0000","spread":"0.00000"},{"groupId":"OG001","value":"0.0000","spread":"0.00000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.7568","spread":"44.49701"},{"groupId":"OG001","value":"102.3939","spread":"69.36822"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"109.0906","spread":"50.65915"},{"groupId":"OG001","value":"119.9343","spread":"54.65786"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"121.7382","spread":"62.62150"},{"groupId":"OG001","value":"133.7669","spread":"58.84136"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetics: Maximum Plasma Concentration [Cmax]","description":"Maximum Plasma Concentration (Cmax) at selected cycles (i.e., Cycle 1, 3, 5 and 7)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"306.0352","spread":"98.71872"},{"groupId":"OG001","value":"302.6362","spread":"87.10467"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"374.9657","spread":"106.54366"},{"groupId":"OG001","value":"399.4598","spread":"136.27431"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"389.3132","spread":"123.07791"},{"groupId":"OG001","value":"397.6183","spread":"125.84175"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"397.5435","spread":"120.74092"},{"groupId":"OG001","value":"426.1350","spread":"144.24538"}]}]}]},{"type":"SECONDARY","title":"Immunogenicity Assessments (Anti-drug Antibodies)","description":"Incidence of anti-drug (bevacizumab) antibodies (ADA)\n\nThe incidence of overall ADA results (i.e. Positive, Negative, Inconclusive) was presented by treatment group at Cycle 7 and the end of treatment (EOT). Overall ADA result was defined as below:\n\n* 'Positive' for a subject with treatment-induced or treatment-boosted ADA, where treatment-induced ADA indicated at least one positive result after pre-dose of Cycle 1 for subjects with negative ADA at pre-dose of Cycle 1, and treatment-boosted ADA indicated at least one positive result with higher titre level compared to pre-dose of Cycle 1 after pre-dose of Cycle 1 for subjects with positive ADA at pre-dose of Cycle 1.\n* 'Negative' for a subject without positive ADA until Cycle 7 and EOT.\n* 'Inconclusive' for a subject with positive ADA at Cycle 1 and without positive result with higher titre level observed after pre-dose of Cycle 1 up to Cycle 7 and EOT.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"15","spread":null}]},{"measurements":[{"groupId":"OG000","value":"357","spread":null},{"groupId":"OG001","value":"356","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29","spread":null},{"groupId":"OG001","value":"22","spread":null}]},{"measurements":[{"groupId":"OG000","value":"309","spread":null},{"groupId":"OG001","value":"316","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"21","spread":null}]},{"measurements":[{"groupId":"OG000","value":"286","spread":null},{"groupId":"OG001","value":"275","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"20","spread":null}]},{"measurements":[{"groupId":"OG000","value":"238","spread":null},{"groupId":"OG001","value":"259","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"9","spread":null}]},{"measurements":[{"groupId":"OG000","value":"129","spread":null},{"groupId":"OG001","value":"152","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"46","spread":null},{"groupId":"OG001","value":"34","spread":null}]},{"measurements":[{"groupId":"OG000","value":"284","spread":null},{"groupId":"OG001","value":"294","spread":null}]},{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"55","spread":null},{"groupId":"OG001","value":"37","spread":null}]},{"measurements":[{"groupId":"OG000","value":"276","spread":null},{"groupId":"OG001","value":"291","spread":null}]},{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Immunogenicity Assessments (Neutralizing Antibodies)","description":"Incidence of anti-drug (bevacizumab) antibodies (ADA) - neutralizing antibodies (NAb) The analysis was performed using the Safety Set (SAF). Overall Number of Participants Analyzed represents the number of subjects in SAF.\n\nThe total number is not the sum of the number of subjects of each visits, since NAb results only for subjects with ADA positive against SB8 or Avastin were used for the summary.\n\nNumber Analyzed of each visit is equal to the number of subjects with ADA positive of each visit, which is displayed in 8. Secondary Outcome: Immunogenicity Assessments (Anti-drug Antibodies).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"9","spread":null}]},{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"8","spread":null}]},{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"11","spread":null}]},{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"5","spread":null}]},{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Best Objective Response Rate by 11 and 17 Weeks","description":"Best Objective Response Rate (ORR) by 11 weeks and 17 weeks","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"107","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"159","spread":null},{"groupId":"OG001","value":"152","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"149","spread":null},{"groupId":"OG001","value":"137","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":81,"n":380},"commonTop":["Alopecia","Anaemia","Nausea","Neutropenia","Thrombocytopenia"]}}}